Tag: Motley Fool

The Costa Group Holdings Ltd (ASX: CGC) share price is soaring this morning after the release of the company’s earnings for 2021.

At the time of writing, the Costa Group share price is $3.25, 8.33% higher than its previous close.

Here are the highlights of the horticultural company’s full-year results for the 2021 calendar year:

Costa Group share price launches on boosted international sales

• Around $1.22 billion of revenue – up from $1.16 billion in 2020
• Total sales of around $1.66 billion
• Earnings before interest, tax, depreciation, and amortisation (EBITDA) of $218.2 million ­– 10.6% higher than 2020
• Net profit after tax (NPAT) before material items of $64 million – 16.2% more than in 2020
• However, NPAT attributable to shareholders fell to $41.4 million ­– a 31% drop
• A 5 cent fully-franked final dividend – equal to that of 2020

2021 was seemingly a strong year for the grower, packer, and marketer of fresh fruit and vegetables.

Over the 12 months ended 26 December, the company’s international segment saw its revenue surge 30%. Now, international customers make up 27% of the company’s sales.

The international segment brought in $177.7 million in 2021. Its EBITDA came to $77 million – a 33% increase.

The company’s produce segment recorded $929.5 million of revenue and EBITDA of $126.6 million ­– relatively flat with 2020.

Finally, its farms and logistics segment saw $159.4 million of revenue – a 6% improvement on that of 2020. However, its EBITDA fell 1.3% to $14.6 million.

Costa Group ended the period with net debt of $299.2 million and $61.9 million in cash and equivalents.

What else happened in the half?

Costa Group’s earnings and sales from berries was strong in 2021. Its premium Arana blueberry variety delivered a 20% price premium while its Tasmanian crop has produced higher than expected volume.

The avocado market, however, saw an increase in supply and was hampered by COVID-19-induced hospitality shutdowns and low price points.

Mushroom production was up 11% in the second half of 2021 and pricing was maintained.

Costa Group’s July acquisition of Queensland-based citrus grower 2PH Farms – costing the company around $200 million, much of which it secured through a capital raise – was completed with 100% customer retention.

The business’ growing season went as expected and 77% of its product was exported.

However, some citrus regions struggled against cool weather in the second half of 2021, causing issues with grown fruit.

Though, the second half was a better time for tomatoes with a 10% improvement in production volumes compared to the first half. Pricing also improved in the second half.

Internationally, China’s berry volumes increased 40% on the prior year, helping to boost revenue by 48%. Morocco’s berry volumes also increased 21% in 2021.

The company’s emerging regions didn’t perform as well. Revenue dropped slightly after delayed crop timing in the United States.

Though, the company provided a 52-week supply of African-grown blueberries to Europe for the first time.

Additionally, many of the company’s segments were impacted by COVID-19-related supply chain issues and labour shortages in 2021.

What did management say?

Costa Group CEO Sean Hallahan commented on the company’s results for 2021, saying:

It was a record year for Costa’s international segment with 30% revenue growth. This supports our investment strategy to expand our production and supply footprint through utilising our world leading blueberry genetics.

The current and projected growth of the middle class in China, the per capita growth in European berry consumption and the opportunities presented by emerging regions, such as India, means Costa is well positioned to benefit as we further invest in growing our international operations.

What’s next?

Looking to what 2022 might bring, Hallahan noted early-season China yield and demand are still above expectations.

Its Moroccan berry harvest is also set to benefit from strong demand.

In Australia, berries and tomato yields had a strong start to 2022, while mushroom production volumes have improved significantly.

In 2022, the company’s return on invested capital (ROIC) will be driven by the beginning of harvesting its new 50-hectare berry farm in China, a full-year contribution from PH2 Farms, 10 new hectares of tomato glasshouse, high volumes of blueberry varieties, and an expected rebound in the company’s Sunraysia grape volumes.

However, avocado production is expected to be below that of 2021 but could be boosted by the return of food service markets.

It’s also a citrus ‘off’-year and COVID-19 impacts will likely continue to impact labour sourcing and supply chains.

Costa Group share price snapshot

Today’s gains have boosted the Costa Group share price back into the green year-to-date.

It is now 7.6% higher than it was at the start of 2022. Though, it’s still around 26% lower than it was this time last year.

The post Fruitful earnings: Costa Group (ASX:CGC) share price surges 8% on full-year results appeared first on The Motley Fool Australia.

More reading

• Analysts name 2 beaten down ASX shares with 30% upside

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended COSTA GRP FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/ygkOLMW

The HUB24 Ltd (ASX: HUB) share price is on the move this morning. At the time of writing, shares are up 5.8% to $24.91.

This follows the release of the financial platform company’s half-year results today.

HUB24 share price jumps on outstanding result

• Group revenue up 72% over prior corresponding period to $81.6 million
• Underlying earnings before interest, taxes, depreciation, and amortisation (EBITDA) up 80% to $29.7 million
• Total funds under administration (FUA) increased by 118% to $68.3 billion
• Record platform net inflows of $6.7 billion, up 116%
• Statutory net profit after tax (NPAT) up 38% to $8.4 million
• Declared fully franked interim dividend of 7.5 cents per share, up 67%

What happened during the first half?

Today’s first-half results are broadly in line with figures shared by the company in its second-quarter update. Surprisingly, the quarterly update provided little excitement for the HUB24 share price. However, investors are getting some additional details.

Notably, HUB24 achieved substantial growth across all of its key metrics. A key driver for the solid performance was the more than doubling in funds under administration. Part of this was the contribution of HUB24’s Xplore acquisition.

While the company mustered up double-digit earnings growth, it also experienced a significant increase in expenses. Specifically, operational expenses rose 68% to $61.3 million. According to the release, this was attributable to growth in employee count.

Management commentary

In light of the result fuelling the HUB24 share price today, CEO and managing director Andrew Alcock said:

We’ve delivered record net inflows and strong financial results including an increase of 80% in group underlying EBITDA, whilst continuing to deliver on our strategic objectives and ensuring we are well-positioned to capitalise on emerging opportunities. We are very excited about the recent acquisition of Class and how together we can lead change in the wealth industry and enhance value for our customers and shareholders.

What’s next?

Interestingly, HUB24 did not provide any guidance for the second half. However, the company did share its ambitions to reach between $83 billion and $92 billion in platform FUA in FY24.

On the dividends front, the board announced it will be targeting a payout ratio of between 40% and 60% of underlying NPAT. The interim dividend announced today reflects a payout ratio of 42%.

Investors should be aware the ex-date for HUB24’s dividend is set for 18 March. From there, shareholders on the register will be paid their dividend on 18 April.

HUB24 share price snapshot

The HUB24 share price has had a rough run in 2022 so far. Since the beginning of the year, shares in the company have tumbled 12%. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has trended around 4% lower.

On a one-year time horizon, ASX-listed HUB24 is up around 6%.

The post HUB24 (ASX:HUB) share price lifts 6% amid record platform inflows appeared first on The Motley Fool Australia.

More reading

• These were the worst performers on the ASX 200 last week
• These were the worst performing ASX 200 shares last week
• 2 quality ASX shares going for dirt cheap right now
• Here are the latest broker updates from Macquarie. It’s not all pretty for ASX shares.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Hub24 Ltd. The Motley Fool Australia has recommended Hub24 Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/l3QzjtU

The Nanosonics Ltd (ASX: NAN) share price is sinking on Tuesday morning.

At the time of writing, the infection prevention company’s shares are down 6% to $4.45 following the release of its half year results.

Nanosonics share price sinks amid softening performance

• Revenue up 41% over the prior corresponding period to $60.6 million
• Global installed base up 12% to 28,160 units
• Operating profit before tax up from $0.2 million to $3.3 million
• Profit after tax up 160% to $3.9 million
• Profit down 45% half on half

What happened during the first half?

For the six months ended 31 December, Nanosonics reported a 41% increase in revenue to $60.6 million. This comprises a 102% increase in capital revenue to $19 million and a 23% lift in consumables and service revenue to $41.6 million.

However, due to COVID impacting the prior corresponding period, a better reflection of the company’s performance is achieved comparing it to the second half of FY 2021. Management revealed that revenue was up 1% compared to the prior half, with capital revenue up 10% but consumables and services revenue down 3%. This reflects some disruption on ultrasound procedure volumes associated with increasing infections rates from the Delta and Omicron variants of COVID-19 including hospital staff shortages in particular in North America.

It was a similar story for Nanosonics’ earnings. While they were up strongly over the prior corresponding period, they were down sharply half on half.

The company reported profit after tax of $3.9 million. This was up 160% over the prior corresponding period but down 45% over the second half of FY 2021. This was driven by an increase in all aspects of its operating costs. This reflects increased spending directed towards expanding capability across all regions, as well as an increase in research and development expenditure.

Management commentary

Nanosonics’ Chief Executive Officer and President, Michael Kavanagh, commented: “The first half of the 2022 financial year has seen strong growth compared with the first half the 2021 financial year, which was materially impacted by COVID-19.”

“Despite the significant and rapid increase in infections in the first half of FY22 associated with the Delta and more recently the Omicron variants and the associated impacts on hospital staff shortages and procedure volumes, the Company maintained the positive momentum achieved in the second half of FY21,” he added.

Outlook

As previously announced, Nanosonics expects to be impacted by the revision to its sales model in North America. However, it is still expecting to deliver double digit sales growth for the year.

It explained: “The impact is expected to be in the range of $13.0 million to $16.0 million and primarily associated with GE transitioning from a stocking distributor to the new pass-through sales model.”

“Assuming the positive market recovery trends experienced in the second quarter of FY22, which have continued in January, in particular in North America and Europe for new installed base growth and consumables usage, we maintain double digit revenue growth expectations despite the FY22 H2 North American revenue impact of the revised North American sales model.”

However, this growth is unlikely to flow to the bottom line, with management predicting a further increase in its operating expenses during the second half.

It advised: “Operating expenses for the first half were $42.7 million and with the addition of the extra resources in North America associated with the revised sales model, total operating expenses are now likely to be approximately $93.0 million.”

This compares to operating expenses of $70.8 million in FY 2021, which represents an increase of 31.3%.

The post Nanosonics (ASX:NAN) share price sinks amid 45% half on half profit decline appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Top brokers name 3 ASX shares to buy next week
• These were the worst performing ASX 200 shares last week
• Top brokers name 3 ASX shares to sell today
• Why Bapcor, Mineral Resources, Nanosonics, and Syrah shares are falling today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Nanosonics Limited. The Motley Fool Australia owns and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/LlmoqFO

The Helloworld Travel Ltd (ASX: HLO) share price closed the day in the red on Monday after the company released its interim report and financial results for the half-year ended 31 December 2021.

Helloworld shares finished the day 4% down at $2.44 apiece as investors responded poorly to the company’s earnings results on Monday.

Helloworld share price tanks amid earnings growth

Key takeouts from the company’s earnings results included:

• Half-year statutory loss after tax fell to $14.0 million compared to $15.1 million in 1H21
• Travel-related revenue grew $12.5 million on the prior corresponding period (pcp), operating costs declined, and short-term net operating cash outflows remained tightly managed
• Total transaction value (TTV) grew 60.4% on the pcp contributing to a 45.2% increase in travel-related revenues
• Margins remained steady at 6%
• Non-corporate and entertainment travel TTV grew 86.6% on pcp
• Earnings before interest, taxes, depreciation, and amortisation (EBITDA) loss of $5.2 million, down 10.8% or $0.6 million on the pcp
• Net loss before tax was $19.6 million, a decline of $1.9 million on the pcp of $21.5 million
• As at 31 December 2021, the group held cash balances of $87.6 million
• Subsequent to period-end, $7.5 million in previously paid company tax was received
• External borrowings at 31 December totalled $70.8 million after repayment of $10 million in December 2021

What else happened this half for Helloworld?

During the period Helloworld agreed to sell (subject to conditions) the corporate and entertainment travel businesses in Australia and New Zealand to Corporate Travel Management Ltd (ASX: CTD), for an enterprise value of A$175 million.

The company also notes its retail agency networks in Australia and New Zealand “remain steadfastly resilient with a strong presence to capture expected growth in travel demand in 2022 and beyond”.

On the back of strong forward bookings, that have continued to climb, significant leisure bookings are now held for travel through until the end of 2023, Helloworld said.

The group expects demand for inbound travel arrivals heading to Australia, New Zealand, and Fiji to gradually normalise in 2022.

“If travel demand continues to grow on its current trajectory, [the company] should achieve a breakeven position or slightly better in the June quarter of FY22 and return to modest profitability throughout FY23,” it said.

Aside from that, travel-related revenue grew $12.5 million year on year whereas operating costs declined. In addition, TTV grew over 60% on the previous year, “contributing to a 45.2% increase in travel-related revenues”.

“With current liquidity levels and cash burn, HLO has sufficient liquidity to maintain operations and continue to benefit from the recovery of the travel and tourism market and to see that through to full recovery,” Helloworld remarked.

Management commentary

In his address, Helloworld chief executive Andrew Burnes said:

Over the last two years, we have reviewed all parts of our business to ensure we are providing all critical services to our agency, corporate and direct customers while keeping costs to a sustainable level.

As part of this review we identified the opportunity to consider divesting our corporate division and on 15 December 2021, HLO announced it had entered into a binding agreement to sell its corporate and entertainment travel businesses in Australia and New Zealand to Corporate Travel Management for an enterprise value of A$175 million. We believe this transaction is at a compelling valuation to maximise HLO shareholder value and will allow HLO to focus on operations which, pre COVID-19, represented 80% of our TTV. Subject to certain conditions being met, completion is expected to occur during the third quarter of FY22.

What’s next for Helloworld?

The company gave an overview of its company expectations for the coming periods. In the near term, Helloworld notes that “pent up demand for travel is extremely strong and when the impacts of the COVID-19 pandemic on travel finally subside, we anticipate travel will ramp up rapidly, with significant growth in the next 24 months”.

If that were the case then demand for travel services from both retail leisure agents and corporate travel management companies will also soar “in a world where professional and personalised travel advice and management will be critical to travellers’ sense of security and comfort”.

Helloworld says it will continue to incur cash losses of approximately $1–$1.5 million per month for the next three months, based on its current expectations.

According to the company, it has a sufficient cash runway to last “beyond the end of calendar 2022 on current liquidity levels and cash burn rate”.

Subject to satisfaction of the conditions and transaction completion, HLO will receive A$100 million in cash and CTM shares of A$75 million (escrowed 12 months from completion) towards the end of the March 2022 quarter. The cash consideration received will be used to repay debt, provide additional liquidity, capital management and to support growth opportunities in HLO’s retail and leisure travel businesses as activity rebounds following COVID-19 disruption.

Helloworld share price snapshot

In the last 12 months, the Helloworld share price has climbed 8%. However, it is down around 3% this year to date. In the past month, it has gained 9%.

The post ‘Losses minimised’ but Helloworld (ASX:HLO) shares can’t hide from the havoc appeared first on The Motley Fool Australia.

More reading

• Why are ASX travel shares taking flight today?
• 2 ASX shares that top analysts are loving right now
• Are ASX travel shares finally emerging from the COVID storm?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Helloworld Limited. The Motley Fool Australia owns and has recommended Helloworld Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/dPtuXFb

The South32 Ltd (ASX: S32) share price has edged higher since announcing its FY22 half year results last Thursday.

The mining outfit delivered strong earnings growth along with a bumper dividend which pleased investors.

Although at yesterday’s market close, South32 shares finished 0.22% lower to $4.56, they are around 2.5% higher since 17 February. This is when the diversified metals miner released its results to the ASX.

What’s the details with the South32 dividend?

In the half year report for the 2022 financial year, South32 reported strong performance across key metrics.

In summary, group statutory profit after tax increased by US$979 million to US$1,032 million in H1 FY22. The company benefited from portfolio changes completed in FY21, as well as a broad recovery in commodity prices.

Underlying earnings jumped by US$868 million to US$1,004 million through higher average realised prices for commodities, particularly metallurgical coal. The latter attributed US$526 million over the period to South32’s coffers.

The group also achieved a US$704 million increase in free cash flow from operations, excluding EAI, to US$840 million.

Overall, the company finished the first half with a net cash of US$975 million, up from US$406 million in the prior year.

The Board declared a fully franked interim dividend of US 8.7 cents per share. This represents a 621% jump from the US 1.4 cents declared in H1 FY21.

Management noted that the latest dividend equates to a payout ratio of 40% of cash earnings.

The company’s dividend policy is to distribute a minimum 40% of cash earnings in half financial year.

It is worth noting that there is a capital management program that has been active since FY18. This returns excess capital efficiently through an on-market share buyback.

The Board further expanded its capital management program by US$110 million to US$2.1 billion, leaving US$302 million to be returned by 2 September 2022.

When can South32 shareholders expect payment?

South32 will pay the interim dividend to eligible shareholders approximately 6 weeks away on 7 April.

To be eligible for the latest dividend, you’ll need to own South32 shares before the ex-dividend date on 10 March. This means if you want to secure the dividend, you will need to purchase South32 shares on or before 9 March.

In case you are wondering, the company is not offering a dividend reinvestment plan (DRP) to shareholders.

The post Banking on the South32 (ASX:S32) dividend? Here’s what you need to know appeared first on The Motley Fool Australia.

More reading

• Why has the South32 (ASX:S32) share price rocketed 60% in 6 months?
• 3 of the best results on the ASX 200 last week
• Morgans names 2 ASX 200 dividend shares to buy now
• Brokers name 3 ASX shares to buy today
• South32 (ASX:S32) share price jumps as profit soars

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/Hkuf5rm

Shares in Sonic Healthcare Limited (ASX: SHL) finished the day down on Monday after the company released its financial results for the half year ended 31 December 2021.

The Sonic Healthcare share price finished the day 3.59% down at $36.25 on Monday after collapsing early in the session.

Sonic Healthcare share price slips despite strong growth

The company outlined several investment highlights, including:

• Revenue growth of 7% to $4.8 billion
• Earnings before interest, tax, depreciation and amortisation (EBITDA) growth of 18% to $1.5 billion
• Net profit growth of 22% to $828 million
• Record financial performance driven by pandemic testing and base business growth
• $585 million invested in synergistic acquisitions/joint ventures in the period with active pipeline of further opportunities
• Base business revenue (ex-COVID testing) up 4.3% versus H1 FY2021 and 2.5% versus H1 FY2020 (constant currency, organic growth)
• Gearing at record low level, approximately $1.4 billion of available liquidity, on-market share buy-back announced as part of active capital management
• Dividend increase of 4 cents (11%) to 40 cents (100% franked) for the FY2022 interim dividend.

What else happened this half for Sonic?

Sonic’s total revenue growth for the half year was 7%, “enhanced by COVID-19 testing revenue in Sonic’s Laboratory division” the company said.

Excluding COVID-19 testing, base revenue grew by 4.3% versus the same period last year, and 2.5% versus H1  – what Sonic calls the pre-pandemic.

While sales grew this half, EBITDA also grew 18%, driven mainly by operating income growth of 20% in the company’s laboratory division, again enhanced by COVID-19 testing.

As such, laboratory division margins lifted off by almost 400 basis points from 30.8% to 34.3%. However, radiology margins were lower “due to pandemic impacts and the relatively low margin of the acquired EMI business”.

The company was pleased with the results that were seen vertically down throughout the profit and loss statement, particularly in terms of efficiency and growth.

“Net profit growth of 22% on 7% growth in revenue demonstrates the operating leverage in Sonic’s businesses”, the company remarked.

Management commentary

Speaking on the announcement, Sonic CEO Dr Colin Goldschmidt said:

Sonic Healthcare’s 38,000 staff have produced outstanding operational and financial performances in the last six months through their unwavering commitment to the tenets of Sonic’s Medical Leadership culture, promoting the provision of exceptional healthcare services. The COVID-19 pandemic continued to throw up new challenges on almost a daily basis, and our people responded magnificently. I sincerely thank all of our staff for their dedication and flexibility during these trying times.

What’s next for Sonic?

Sonic announced on 21 February 2022 that it wanted to undertake an on-market share buy-back of its shares. It has the approval of up to $500 million, per the release.

Aside from that, no formal guidance was provided by the company.

Sonic Healthcare share price snapshot

In the last 12 months, the Sonic Healthcare share price has climbed 9.09%. This year to date, however, it has struggled and is down 22%.

Even in the past month, shares have fallen almost 7% and are sliding by around 3% over the previous week of trading.

The post Record financials not enough: Sonic Healthcare (ASX:SHL) share price sinks post-earnings appeared first on The Motley Fool Australia.

More reading

• 2 compelling ASX 200 shares that keep growing their dividends
• Why this top broker just downgraded these 2 ASX healthcare shares
• Why are ASX COVID test shares climbing today?
• 2 ASX shares every dividend investor needs to know about

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/IFoX8v4

Shares in Reliance Worldwide Corporation Ltd (ASX: RWC) closed Monday up marginally after the company released its interim report and financial results for the half year ended 31 December 2021.

The RWC share price finished the day less than 1% in the green at $5.13 following the release of its earnings results today.

RWC share price flat amid earnings growth

Key takeouts from the company’s earnings results include:

• 12% growth in reported Net Sales to US$522 million over the prior corresponding period (pcp)
• Americas growth of 15% over pcp including an initial contribution from EZ-FLO which was acquired in November 2021
• Asia Pacific constant currency sales up 10% on pcp driven by strong Australian residential construction and remodel activity
• Continental Europe sales up strongly, while the UK saw lower volumes following a strong period of growth in the pcp
• Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of US$125.5 million, up 5% on pcp
• Adjusted net profit after tax (NPAT) of US$75.4 million, up 5% on pcp

What else happened this period for RWC?

The company’s performance this half was hallmarked by NPAT of US$63.7 million for the six months whereas Adjusted NPAT spiked 5%, up to US$75.4 million.

The result enabled RWC’s board to declare an interim dividend of US4.5 cents per share, slightly down on previous payments in 2021.

However, RWC wasn’t immune to the impacts that global supply chain pressures had on commodity prices in 2021. Rising costs for materials like copper, resins, and steel, were experienced during the period “together with higher costs for freight, packaging, energy and other costs”.

Whilst the company attempted to pass the costs onto consumers versus absorbing it themselves, it remains to be seen whether RWC has the pricing power in its segment to pull this off successfully.

“Price rises were implemented during the period to substantially offset these increased costs, although the timing lag between higher input costs being incurred and offsetting price increases negatively impacted operating margins”, it remarked.

In good news, the period included the first contribution from EZ-FLO, which was acquired back in November 2021. The segment contributed sales of US$22.5 million and EBITDA of US$2.3 million recorded for the 6-week period post-acquisition, RWC says.

Management commentary

Speaking on the announcement, RWC Chief Executive Officer Heath Sharp said:

We continued to experience robust market conditions and demand for our products. The trend of increased spending on home remodelling activity, coupled with strong new residential construction markets, has underpinned record levels of demand. We were able to consolidate our volumes following a period of exceptional growth in 2021. Importantly, we were able to meet our customer’s service and delivery expectations despite the increased incidence of COVID and supply chain challenges.

What’s next for RWC?

So far, this year to date, trends have been “broadly consistent with the trends seen in the first half”, the company said, although results have been mixed.

“Americas sales, excluding EZ-FLO, were higher than the same month last year reflecting ongoing strong demand and performance ahead of market. APAC external sales continued to benefit from ongoing strength in the residential construction and remodelling markets in Australia”, it said.

“Europe, Middle East and Africa (EMEA) also continued the trajectory of the first half with the overall result in line with the prior January”.

RWC share price snapshot

In the last 12 months, the RWC share price has climbed 8% but has struggled since trading recommenced on January 4. Since then it has collapsed over 18%.

The post ‘Record demand’ not enough to lift RWC (ASX:RWC) share price on Monday appeared first on The Motley Fool Australia.

More reading

• Record financials not enough: Sonic Healthcare (ASX:SHL) share price sinks post-earnings
• Strong rebound sees EVT (ASX:EVT) share price lunge 5% higher on Monday
• Why the RPMGlobal (ASX:RUL) share price is edging higher this week
• Clinical trials not enough to stop Noxopharm (ASX:NOX) shares’ 5% plunge on Monday
• Coles (ASX:COL) share price on watch after COVID costs hit earnings

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Reliance Worldwide Corporation Limited. The Motley Fool Australia has recommended Reliance Worldwide Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/paZcbMB

Shares in Event Hospitality and Entertainment Ltd (ASX: EVT) closed Monday in the green after the company released its interim report and financial results for the half year ended 31 December 2021.

The EVT share price finished Monday 5% higher at $15.30 as investors bought in following the release of its earnings results.

EVT share price lunges higher amid earnings growth

Key takeouts from the company’s earnings results include:

• Group normalised revenue was $438 million, up $155.1 million or 54.8% on the previous year
• Normalised EBITDA was $64.1 million, up $95.1 million on the prior comparable half year
• Statutory profit after tax was $33.3 million, a $93.6 million improvement on the prior comparable half year reported loss.
• Divestments in non-core assets on-track: $194.4 million to date, with gross proceeds to date exceeded most recent valuations by 35.1%.
• Divestments and improved trading performance reduced net debt to $292.3 million at 31 December 2021, consistent with pre-COVID-19 levels.

What else happened this half for EVT?

The company noted that it faced “materially tougher government mandated restrictions than [the] prior comparable period”, like all businesses in Australia during 1H FY22.

Nevertheless, group revenue can in almost 55% higher year on year at $438 million, although that figure reduces to just 35% when backing out the German Government’s Bridging Aid III support the company received.

EVT also said its entertainment businesses benefited from |pent-up demand for the cinema experience and strong performance of key blockbuster films Spider-Man: No Way Home and No Time to Die.

EVT owns the largest cinema circuits in Australia, New Zealand and Germany under the brands Event Cinemas, Greater Union, Moonlight Cinemas and CineStar just to name a few.

And weren’t the group’s growth initiatives on fully display this half as well, particularly through add-on sales generated from its ‘Cinema of the Future’ agenda.

“Implementation of the Cinema of the Future strategies to leverage this demand resulted in customers spending
more each visit and generated a higher profit per customer on a like film basis”, it said.

Aside from this, the group says it continued to make good progress on the divestment strategy with sales in the half year realising gross proceeds of $107.9 million. Cumulatively, the company has now generated gross proceeds of $194.4 million, “exceeding the most recent valuations by 35.1%”.

Management commentary

Speaking on the announcement, EVT CEO Jane Hastings said:

In this half year period, the Group navigated materially greater government lockdowns and restrictions than the prior comparable period. Despite this, the transformation strategies and actions we have completed over the past few years, ensured we are agile and able to respond to the ever-changing landscape. This is evident in the revenue growth and EBITDA turnaround for the Group in this period, which included $75 million of active cost management. Our new business models are already delivering evidence of improved margins which we expect to continue post the pandemic. We have a strong balance sheet and Group net debt is down to pre-COVID level. We are in a strong position to navigate current challenges and invest for growth. I am incredibly proud of the entire EVT team and the way everyone continues to innovate and adapt to deliver the best possible results.

What’s next for EVT?

Commenting on the outlook for 2022, Hastings noted that demand for the cinema experience will remain strong when restrictions are lifted. Based on its current pipeline, the company expects box office revenue “to exceed that achieved in the second half of the prior financial year” for H2 FY22.

Signs of recovery for Hotels were evidenced in the December trading period before Omicron, including pleasing growth in the average room rate, and in Australia, corporate travel is expected to gain traction from April. Thredbo’s summer season is tracking relatively in line with the prior summer season. Overall, our underlying Group EBITDA in the second half last year was approximately $15 million excluding the German Government’s November and December 2020 aid program, and we expect underlying Group EBITDA in the second half this year to demonstrate a strong improvement on that result, subject to no further government trading restrictions.

EVT share price snapshot

In the last 12 months, the EVT share price has climbed 47% after spiking another 3% this year to date. In the past month, it has also soared almost 10% and is in the green across all time frames.

The post Strong rebound sees EVT (ASX:EVT) share price lunge 5% higher on Monday appeared first on The Motley Fool Australia.

More reading

• Why the RPMGlobal (ASX:RUL) share price is edging higher this week
• Clinical trials not enough to stop Noxopharm (ASX:NOX) shares’ 5% plunge on Monday
• Coles (ASX:COL) share price on watch after COVID costs hit earnings
• Is the Webjet (ASX:WEB) share price about to fly higher?
• Earnings boost: Ooh!Media (ASX:OML) share price spikes 5% with audience rebound

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/T9aIrPJ

The RPMGlobal Holdings Ltd (ASX: RUL) share price is hovering in positive territory so far this week.

While the All Ordinaries (ASX: XAO) gained just 0.06% on Monday, sitting at 7,507 points, RPMGlobal shares managed to leap 2.22% to close the day at $1.84.

This follows the release of the mining software company’s first-half results for the 2022 financial year.

Let’s take a look at what RPMGlobal reported for the front end of FY22.

RPMGlobal share price advances after booking growth across key metrics 

The RPMGlobal share price pushed higher on the back of the company’s latest results.

For the 6 months ending 31 December 2021, RPMGlobal achieved growth despite COVID-19 impacting the business. Here are some of the key highlights:

• Total group revenue of $40.5 million, up 12% on the prior six-month period (H2 FY21)
• Underlying operating earnings before interest, tax, depreciation and amortisation (EBITDA) of $3.9 million, up 457% on H2 FY21
• Net profit of $1.9 million, up $8.3 million on H2 FY21
• No interim dividend declared for the first half.

What happened in H1 FY22 for RPMGlobal?

RPMGlobal experienced a strong first-half operating performance, driven by an increase in software revenue and advisory revenue. The segments delivered earnings of $27.8 million, up 23.6%, and $12.7 million, up 64.9%, respectively on the prior year.

Operating expenses came to $34.2 million for the first half due to the acquisition of two Environmental and Social Governance businesses. These were Nitro Solutions and Blueprint Environmental Strategies, for which RPMGlobal paid a total of $3.9 million in completion payments.

The group has been focusing on moving its software solutions into the cloud which resulted in higher development costs.

At the end of the period, RPMGlobal recorded net assets of $65.8 million, including cash of $32.4 million and no debt.

What’s the outlook for RPMGlobal?

Looking ahead, RPMGlobal believes operations will return to normal settings by July following the gradual reopening of borders.

The company estimates that a lift in software sales will materialise once mining countries are open for business.

Management noted that selling complex software solutions to global companies is best done in person rather than online.

The company’s ESG division is expected to continue performing in the second half, heavily contributing to revenue in the advisory segment.

While the company maintains a positive outlook, given the unpredictable nature of the pandemic, RPMGlobal refrained from providing FY22 full-year earnings guidance.

The post Why the RPMGlobal (ASX:RUL) share price is edging higher this week appeared first on The Motley Fool Australia.

More reading

• Strong rebound sees EVT (ASX:EVT) share price lunge 5% higher on Monday
• Clinical trials not enough to stop Noxopharm (ASX:NOX) shares’ 5% plunge on Monday
• Coles (ASX:COL) share price on watch after COVID costs hit earnings
• Is the Webjet (ASX:WEB) share price about to fly higher?
• Earnings boost: Ooh!Media (ASX:OML) share price spikes 5% with audience rebound

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended RPMGlobal Holdings. The Motley Fool Australia has recommended RPMGlobal Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/d7UE8Vp

Shares in Noxopharm Ltd (ASX: NOX) closed the day in the red after the company released its interim report and financial results for the half year ended 31 December 2021.

The Noxopharm share price finished the day 5% down at 38 cents as investors responded poorly to the release of its earnings results today.

Noxopharm share price as clinical trials progress

Key takeouts from the company’s earnings results today include:

• Strong cash position of A$22.6m due to continued judicious expenditure in the best interest of the company and its shareholders
• This amount includes $5.9 million R&D tax incentive for FY21 received in January 2022, considered non-dilutive funding for the company
• Increased investment in R&D of $8.3m compared to $3.0 million in 1HFY20 to advance the clinical trial programs
• DARRT Program Phase 2 clinical trial (Veyonda with low-dose radiotherapy received IND approval from the FDA

What else happened this half for Noxopharm?

The company’s progress was hallmarked by clinical trial and drug discovery momentum, particularly as R&D expenditure increased by over $5 million to support these programs.

Noxopharm says that its clinical trial sites “include some of the leading cancer centres in the world, notably, the US number one cancer hospital, the MD Anderson Cancer Center…as well as the Beverly Hills Cancer Center and the City of Hope Cancer Center”.

During the half, Noxopharm’s DARRT Program Phase 2 clinical trial, investigating Veyonda with low-dose radiotherapy, received investigational new drug (IND) approval from the Federal Drug Administration (FDA).

As such, the company says the trial is underway at two leading U.S. cancer centres – the MD Anderson Cancer Center and the Beverly Hills Cancer Centre. The patient cohort has already completed first dosages and completed the safety assessments, so updates should be on the way later this year.

Not only that, but Noxopharm made progress on the IONIC Phase 1 trial it is conducting with Bristol Myers during the half. The trial is investigating Veyonda with the Bristol Myers Squibb checkpoint inhibitor, nivolumab, that sells under the brand name Opdivo.

Patients have already been enrolled and treated at the first clinical site the company says, and more sites are expected to open in H1 2022.

Management commentary

Speaking on the announcement, incoming CEO of Noxopharm, Dr Gisela Mautner said:

As incoming CEO, it is pleasing to report that Noxopharm is in a strong cash position with a number of promising programs underway. Our Clinical Portfolio, investigating the combination of Veyonda® with established cancer treatments, is tracking to plan. It is also important to note the relationships we have secured with national and international partners such as Hudson Institute of Medical Research and the US National Cancer Institute, as well
as several prestigious clinical study sites in the USA.

What’s next for Noxopharm?

The company will endeavour to progress in its clinical trial and drug discovery programmes as outlined in its earnings report on Monday.

Noxopharm did not provide any specific earnings or cost guidance for the remainder of FY22.

Noxopharm share price summary

In the last 12 months, the Noxopharm share price has plunged 52% and sits 3% in the red since we started trading in 2022.

Over the previous month, shares have faltered another 9% and are down 9% this past week too.

The post Clinical trials not enough to stop Noxopharm (ASX:NOX) shares’ 5% plunge on Monday appeared first on The Motley Fool Australia.

More reading

• Coles (ASX:COL) share price on watch after COVID costs hit earnings
• Is the Webjet (ASX:WEB) share price about to fly higher?
• Earnings boost: Ooh!Media (ASX:OML) share price spikes 5% with audience rebound
• Why new iron projects could drive the Fortescue (ASX:FMG) share price higher
• Rate rise coming? 2 finance ASX shares to buy right now

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/b8UYBGR